Related Experiment Videos
Baclofen (para-chlorphenyl-GABA) in schizophrenia
Pharmakopsychiatrie, Neuro-Psychopharmakologie
|January 1, 1977
Summary
This study found that baclofen did not improve schizophrenia symptoms in patients. The drug showed no benefit and led to worsening symptoms or psychotic exacerbations in many participants.
Area of Science:
- Psychiatry
- Clinical Pharmacology
Background:
- Schizophrenia is a complex psychiatric disorder with limited effective long-term treatments.
- Baclofen, a GABAergic agent, has been explored for various neurological and psychiatric conditions.
Purpose of the Study:
- To evaluate the efficacy and safety of baclofen (para-chlorphenyl-GABA) in treating schizophrenia.
- To assess baclofen's impact on overall clinical impression, psychotic symptoms, and specific symptom clusters in schizophrenic patients.
Main Methods:
- A single-blind study involving 21 schizophrenic patients.
- A placebo-controlled trial with a 20-day treatment period of baclofen following a placebo phase.
- Clinical global impression, AMP documentation system, and assessment of Schneiderian first-rank symptoms were utilized.
Main Results:
- Baclofen administration resulted in no significant change in the overall incidence of psychotic symptoms.
- Nine patients worsened, and four required withdrawal due to severe psychotic exacerbations.
- No differential effects were observed on first-rank symptoms or chronic defectuous schizophrenia symptoms.
Conclusions:
- Baclofen is not considered an effective therapeutic agent for schizophrenia.
- The drug demonstrated a lack of efficacy and potential for adverse psychiatric events in this patient population.